Transfer technology expert expands US presence following multi-million-pound investment
Investment follows demand for the company's AseptiSafe and PharmaSafe product ranges, which transfer APIs in small- and large-scale pharmaceutical manufacturing environments.
Powder containment and aseptic transfer valve specialist ChargePoint Technology is expanding its US presence, following a multi-million-pound investment from LDC.
The Liverpool, UK headquartered company struck a deal with the private equity firm in January 2017 to capitalise on the strong demand for its solutions in North America, Europe and Asia. This includes the AseptiSafe and PharmaSafe product ranges, which are used to ensure the safe transfer of active pharmaceutical ingredients (APIs) in small- and large-scale pharmaceutical manufacturing environments.
This demand has fuelled the need for the expansion of the firm’s support team within North America. A new office, based in San Francisco, brings the total number of offices globally to four with other locations including Hong Kong and New Jersey.
Chris Rombach, previously of ILC Dover, Pacific Ozone and Stedim Biotech (now part of Sartorius group) joins the team at the San Francisco office as President of ChargePoint Inc. He will be responsible for driving the growth of the entire ChargePoint offering across the US, Canada, Mexico and Puerto Rico. This will include the establishment of local sales operations and the creation of new roles in the US, as well as new reseller channels. The company has plans to double its global workforce by 2020.
Chris Eccles, CEO of ChargePoint commented: “Growing our North American presence is a significant milestone for us and reflects our strategic vision to expand the company in key markets. Our product range and AfterCare support mean we are ideally placed to meet the increasing demand for safe containment and sterile transfer solutions. The use of split-valve technology is growing in popularity, and can offer an alternative to more cumbersome and costly containment techniques.
“Continuing our investment in our business and enhancing the service we can provide our customers at a local level has been our main priority in 2017 so far, and bringing on board new team members with the strategic vision to grow the company globally is key to our goals. We are very pleased to have Chris on board as part of our North America team and have no doubt his industry expertise is a perfect fit for the ChargePoint business.”
Chris’ previous experience spans across several manufacturing and engineering companies within the biopharmaceutical and bioprocessing markets, providing him with extensive technical expertise across bio-processing and containment systems, as well as experience in business development and strategic growth planning.
Commenting on his new position within ChargePoint, Chris Rombach said: “To be joining ChargePoint at a time when it is experiencing significant growth and investment is very exciting. Having the opportunity to support the sale of such revolutionary products, that are receiving demand across the globe, is something I’m looking forward to being part of.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance